On August 31, BEONE MEDICINES fell 3.39% in regular trading, trading at HK$214.2/share, with turnover of HK$138 million. The stock has been under sustained selling pressure since the release of its interim results on August 26.

The company reported H1 revenue of RMB 22.22 billion, up 26.84% year-over-year, and net profit attributable to shareholders of RMB 3.271 billion, surging 627.15% YoY. However, Q2 standalone net profit grew only approximately 3% quarter-over-quarter, while revenue growth continued to decelerate. The market has grown divided over the sustainability of the high-growth trajectory. On the A-share side, the stock fell 6.07% last week, with net main fund outflows exceeding RMB 75 million on August 28 alone.

Additionally, executive Ou Leiqiang sold approximately US$19.66 million worth of shares on August 12, further weighing on sentiment. The broader biotech sector is also under pressure, with peers AKESO down 3.2%, INNOVENT BIO down 3.63%, and CANSINOBIO down 6.8%, reflecting broad-based profit-taking across the industry.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)